Pfizer Abandons Weight Loss Drug, Stock Drops.
TL;DR Summary
Pfizer has discontinued the development of its once-a-day experimental obesity pill, lotiglipron, due to concerns about liver safety. However, the company will continue developing its twice-daily treatment, danuglipron, as it competes with other weight loss treatments. Pfizer CEO Albert Bourla has said that an obesity pill could eventually be a $10-billion-a-year product for Pfizer. The news comes after competitor Eli Lilly released promising data for its own once-daily experimental pill, orforglipron.
- UPDATE 3-Pfizer scraps one weight loss drug in race to develop Ozempic rival Yahoo Finance
- Pfizer Sells Off After Discontinuing Weight Loss Drug The Wall Street Journal
- Pfizer drops oral obesity drug after seeing liver safety concern, focuses on less-convenient candidate FierceBiotech
- Pfizer scraps one weight loss drug in race to develop Ozempic rival Yahoo! Voices
- Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Investor's Business Daily
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
2 min
vs 3 min read
Condensed
83%
425 → 71 words
Want the full story? Read the original article
Read on Yahoo Finance